Chromadex Corp Stock OTC Bulletin Board
Stocks
CDXC
US1710771007
Biotechnology & Medical Research
|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| 11-05 | Niagen Bioscience, Inc., Q3 2026 Earnings Call, Nov 04, 2026 | |
| 11-05 | Niagen Bioscience, Inc. Provides Earnings Guidance for the Year 2026 | CI |
| Market Cap | 181M 162M 149M 135M 256M 16.96B 262M 1.78B 709M 9.08B 679M 665M 28.6B | P/E 2026 * |
50.7x | P/E 2027 * | 47.2x |
|---|---|---|---|---|---|
| Enterprise Value | 181M 162M 149M 135M 256M 16.96B 262M 1.78B 709M 9.08B 679M 665M 28.6B | EV / Sales 2026 * |
1.53x | EV / Sales 2027 * | 1.32x |
| Free-Float |
70.57% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Chromadex Corp
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Fried
CEO | Chief Executive Officer | 66 | 01/06/2018 |
Ozan Pamir
DFI | Director of Finance/CFO | 35 | 21/10/2024 |
Mona Rosene
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Jaksch
CHM | Chairman | 57 | 22/06/2018 |
Robert Fried
BRD | Director/Board Member | 66 | 09/07/2015 |
Steven Rubin
BRD | Director/Board Member | 65 | 27/03/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.24% | +8.40% | +58.47% | +69.00% | 66.7B | |
| +4.66% | +8.90% | +16.93% | +85.41% | 56.88B | |
| -0.60% | +1.73% | +24.32% | +94.40% | 56.53B | |
| +2.55% | +15.52% | +30.43% | +120.17% | 46.49B | |
| +2.58% | +7.89% | +32.49% | +45.30% | 44.8B | |
| +4.09% | +6.37% | +228.06% | +899.75% | 41.59B | |
| -0.47% | +9.38% | +27.53% | +52.40% | 35.35B | |
| +3.80% | -1.00% | +98.16% | +66.79% | 33.29B | |
| +1.48% | +6.21% | -38.80% | +395.73% | 25.1B | |
| Average | +2.26% | +6.63% | +53.07% | +203.21% | 45B | |
| Weighted average by Cap. | +2.29% | +7.27% | +53.75% | +181.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 118M 106M 97.26M 88.27M 167M 11.1B 171M 1.16B 464M 5.94B 444M 435M 18.71B | 137M 122M 113M 102M 194M 12.85B 198M 1.35B 537M 6.88B 515M 504M 21.67B |
| Net income | 4.31M 3.85M 3.54M 3.21M 6.09M 404M 6.24M 42.37M 16.89M 216M 16.18M 15.84M 681M | 3.23M 2.88M 2.65M 2.41M 4.56M 303M 4.68M 31.74M 12.65M 162M 12.12M 11.86M 511M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NAGE Stock
- CDXC Stock
Select your edition
All financial news and data tailored to specific country editions
